Lexogen upgrades the TeloPrime Full-Length cDNA Amplification Kit empowering multiple downstream applications

Vienna, Austria, December 17, 2018 / PRNewswire/ – Today Lexogen launches a Version 2 (V2) upgrade for the TeloPrime Full-Length cDNA Amplification Kit; an all-in-one protocol for generating 5’ cap-specific full-length cDNA from as little as 1 ng of total RNA. The new TeloPrime V2 Kits provide higher yields and enhanced representation of longer cDNAs than the... Read more

Crown Bioscience Creates Center of Excellence for Bioinformatics, Big Data, and Biomarker Discovery Services

December 18, 2018 ~ Services and Capacity Increase with New Site Opening ~ (San Diego, Calif., December 13, 2018) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has recently announced the expansion of its existing translational oncology research capacity by opening... Read more

10x Genomics Acquires Spatial Transcriptomics

Stakes Claim in Emerging Spatial Genomics Space PLEASANTON, CA.—December 10, 2018—10x Genomics today announced the acquisition of Stockholm-based Spatial Transcriptomics, a pioneer in the emerging field of spatial genomics. The new field enables researchers to not only see what is in a cell but how cells are organized in relation to one another, offering up invaluable insight... Read more

Merck KGaA, Darmstadt, Germany Announces a CRISPR/Cas9 Strategic Alliance to Develop Rodent Models with genOway

10 DEC 2018 | DARMSTADT, GERMANY genOway to acquire exclusive rights to Merck’s foundational genome-editing patents to produce, sell rodent models New technologies and solutions to be developed using CRISPR/Cas9 to accelerate delivery of better drugs to patients Merck KGaA, Darmstadt, Germany, a leading science and technology company and leader in genome editing, announced that its life... Read more

Illumina Announces a New Genotyping Array and Scientific Contribution to Three Genome Centers to Support the All of Us Research Program

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced the launch of its new high-density genotyping array, the Infinium™ Global Diversity Array. This new array was developed for and inspired by the All of Us Research Program. The All of Us Research Program is a historic effort to gather data from one million or more people living in... Read more

NRGene Announces Expanded Licensing Agreement with Bayer for the GenoMAGIC Platform

Following successful evaluation, Bayer has chosen the GenoMAGICTM platform to support its advanced molecular breeding program in several key crops Ness Ziona, Israel – (December 3, 2018) –NRGene, the worldwide leader in genomic analysis, announces a key milestone in its multi-year licensing agreement with Bayer for the use of GenoMAGICTM, a cloud-based big data analytics platform... Read more

QIAGEN launches QCI Interpret bioinformatics features for use for blood cancers as well as a novel myeloid gene panel for GeneReader NGS System

Hilden, Germany, and Germantown, Maryland, November 29, 2018 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of two novel products to deliver actionable insights on a wide range of blood cancers: a new workflow for the QIAGEN Clinical Insight (QCI) Interpret bioinformatics solution for hematological malignancies, and the new QIAact Myeloid... Read more

Swift Biosciences Launches Normalase™, Radically Streamlining and Improving NGS Library Normalization

(ANN ARBOR, Mich. – November 28, 2018) Swift Biosciences today announced the availability of its eagerly anticipated Normalase™ Kit, a revolutionary enzymatic library normalization product that streamlines the cumbersome steps following next-generation sequencing (NGS) library preparation. Compared to conventional normalization, Swift Normalase saves cost on sequencing by reducing read depth variation within a pool down to... Read more

QIAGEN extends comprehensive offering for cervical cancer screening with European launch of QIAscreen HPV PCR Test

Hilden, Germany, November 28, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAscreen HPV PCR Test, a CE-IVD marked molecular diagnostic test for the detection of 15 recognized high-risk genotypes of human papillomavirus (HPV), the virus considered to be the cause of cervical cancer. The assay includes... Read more

MilliporeSigma Wins Two R&D 100 Awards for Innovation in 2018

27 NOV 2018 | DARMSTADT, GERMANY MilliporeSigma’s proxy-CRISPR wins Special Recognition Market Disruptor — Products award Burlington, Massachusetts, November 27, 2018 – MilliporeSigma today announced that it has won two R&D 100 Awards. The 56th annual R&D 100 Awards program, honoring the 100 most innovative and significant technologies introduced in the past year, recognized MilliporeSigma for its BioReliance® Viral and Gene Therapy Assay... Read more